lobbying_activities: 3438016

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3438016	b06aa48c-4220-4401-b6cb-95f10234db6e	Q3	DLA PIPER LLP (US)	76855	BIOTECHNOLOGY INNOVATION ORGANIZATION	2025	third_quarter	MED	Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2025-10-16T16:24:37-04:00